Garcia Marino 4

What Happened
Garcia Marino, CEO, President and Director of Dianthus Therapeutics (DNTH), exercised 122,918 option-derived shares on March 12, 2026 at $6.70 per share (cost $823,551) and sold those same 122,918 shares in multiple open-market transactions that day for aggregate proceeds of approximately $10.02 million. The sales were executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: March 12, 2026; Form 4 filed March 13, 2026 (timely filing).
• Exercise: 122,918 shares acquired at $6.70 each — total cash paid $823,551.
• Sales (total disposed = 122,918 shares; total proceeds ≈ $10,016,381):
  • 43,505 shares @ weighted avg $80.69 (prices in range $80.29–$81.28) — $3,510,418.
  • 65,517 shares @ weighted avg $81.74 (range $81.29–$82.25) — $5,355,360.
  • 12,796 shares @ weighted avg $82.60 (range $82.29–$83.23) — $1,056,950.
  • 200 shares @ $83.38 — $16,676.
  • 900 shares @ $85.53 — $76,977.
• An additional derivative-line shows 122,918 shares reported as disposed at $0.00 (reporting of the exercised conversion).
• Footnotes: trades executed pursuant to a Rule 10b5-1 plan adopted Nov 17, 2025; several weighted-average price notes provide the price ranges for the multiple transactions; original option vesting schedule noted.
• Shares owned after the transactions: not disclosed in the excerpt of this filing.

Context
Because the shares were acquired by exercising options and then sold the same day, this is effectively a cashless exercise (exercise + immediate sale). Sales executed under a 10b5-1 plan are pre-arranged and are often routine executions of planned dispositions rather than ad hoc signals of insider sentiment.